← Back to Search

Tyrosine Kinase Inhibitor

Daily dose of CK-101 for Adenocarcinoma

Phase 1
Waitlist Available
Research Sponsored by Checkpoint Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Measureable disease according to RECIST Version 1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (first dose) until disease progression or withdrawal from study, expected average 10 months
Awards & highlights

Study Summary

This study is evaluating whether a drug called CK-101 can be used to treat lung cancer.

Eligible Conditions
  • Adenocarcinoma
  • Lung Disease
  • Non-Small Cell Lung Cancer
  • Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (first dose) until disease progression or withdrawal from study, expected average 10 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (first dose) until disease progression or withdrawal from study, expected average 10 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase I: Incidence of dose-limiting toxicities (DLTs)
Phase II: Objective response rate (ORR): Defined as the rate of complete responses [CR] or partial responses [PR] per RECIST Version 1.1 as assessed by an independent central review
Secondary outcome measures
Phase I: Change from baseline in QT/QTc interval
Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by area under the curve
Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by elimination half-life
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Daily dose of CK-101Experimental Treatment1 Intervention
Daily oral dose of CK-101
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CK-101
2016
Completed Phase 1
~140

Find a Location

Who is running the clinical trial?

Checkpoint Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
525 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
2016. "Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02926768.
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top